Table 2.
ICI usage patterns in patients on active ICI treatment* (n=25)
| Characteristics | Continued their ICI (n=18) |
Held their ICI (n=7) |
| Female, n (%) | 8 (44) | 5 (71) |
| Age, mean (SD) | 64.4 (12.2) | 66.6 (11.3) |
| Caucasian, n (%) | 15 (83) | 6 (86) |
| BMI, mean (SD) | 29.5 (12.3) | 34.7 (11.2) |
| Hypertension, n (%) | 8 (44) | 2 (29) |
| Diabetes, n (%) | 4 (22) | 0 |
| Pulmonary disorder, n (%) | 0 | 1 (14) |
| Cancer type, n (%) | ||
| Melanoma | 3 (17) | 2 (29) |
| Renal | 4 (22) | 0 |
| Urothelial | 3 (17) | 3 (43) |
| NSCLC | 2 (11) | 1 (14) |
| Other | 6 (33) | 1 (14) |
| ICI regimen, n (%) | ||
| Monotherapy | 12 (67) | 7 (100) |
| Combination | 6 (33) | 0 (0) |
| Cancer response, n (%) | ||
| CR/PR/stable | 15 (83) | 7 (100) |
| Progression | 3 (17) | 0 |
| Immunosuppression† | ||
| No medications | 4 (22) | 2 (29) |
| NSAIDs | 2 (11) | 1 (14) |
| Steroids | 9 (50) | 4 (57) |
| HCQ | 2 (11) | 1 (14) |
| MTX | 2 (11) | 0 |
| Anti-TNF | 2 (11) | 0 |
| Tocilizumab | 1 (6) | 0 |
*Active ICI treatment = has received ICI within 6 months of survey.
†Totals do not add up to 100% given that patients can be on multiple medications at a given time.
BMI, body mass index; CR, complete response; HCQ, hydroxychloroquine; ICI, immune checkpoint inhibitor; irAE, immune-related adverse effect; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; NSCLC, non-small cell lung cancer; OA, osteoarthritis; PMR, polymyalgia rheumatica; PR, partialresponse; TNF, tumor necrosis factor.